萸竹定眩丸治疗痰浊阻络型眩晕的疗效及对外周血FGF-21水平的影响
|
摘要
目的:评价萸竹定眩丸对痰浊阻络型眩晕的治疗效果及对外周血FGF-21水平的影响。方法:120例患者随机分为治疗组和对照组,对照组口服盐酸氟桂利嗪胶囊10mg,每晚1次;治疗组在对照组的基础上给予萸竹定眩丸,每次1丸,每日2次;两组均治疗14天。14天后比较两组患者临床疗效、血脂及外周血中FGF-21水平。结果:治疗组总有效率为93. 3%,对照组总有效率为66. 7%,两组总有效率比较有统计学差异(P <0. 05);治疗后两组FGF-21水平均较治疗前明显降低(P <0. 01,P <0. 05),且治疗组FGF-21水平比对照组降低更明显(P <0. 05);治疗后,两组的TC、TG、LDL-C水平均较治疗前明显下降,HDL-C水平均较治疗前明显升高(P <0. 01),且治疗组的TC水平比对照组下降更显著,HDL-C水平比对照组上升更显著(P <0. 01)。结论:萸竹定眩丸治疗椎-基底动脉供血不足性眩晕(中医辨证属痰浊阻络型眩晕)具有明确疗效;萸竹定眩丸对改善人体的糖脂代谢水平,降低TC,升高HDL-C疗效明确;萸竹定眩丸在临床应用中未发现严重不良反应,临床应用安全可靠。
引文
[1]周丽萍.眩晕的流行病学调查研究[J].中国实用神经病学杂志,2010,13(18):31-32.
[2]潘婕,罗本燕.眩晕的诊断与鉴别诊断[J].中国实用内科杂志.2011,31(6):421-423.
[3]王维治.神经病学[M]. 5版.北京:人民卫生出版社,2005:20-22.
[4]周仲瑛.中医内科学[M].北京:中国中医药出版社,2007:299.
[5]郑筱萸.中药新药临床研究指导原则(试行)[S].北京:中国医药科技出版社,2002:24.
[6]景小莉,崔应麟.萸竹定眩丸治疗痰浊中阻型眩晕40例[J].中国中医药现代远程教育,2010,8(15):12.
[7]Matuszek B,Lenart-Lipinska M,Duma D,et al. Evaluation of concentrations of FGF-21-a new adipocytokine in type 2 diabetes[J]. Endokrynologia Polska,2010,61(1):50-54.
[8]Mraz M,Barlova M,Lacinova Z,et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity[J]. Clin Endocrinol,2009,71(3):369-375.
[9]Omar BA,Andersen B,Hald J,et al. Fibroblast growth factor 21(FGF21)and glucagon like peptide I contribute to diabetes resistance in glucagon receptor deficient mice[J]. Diabetes,2014,63(1):101-110.
[10]Holland W L,Adams A C,Brozinick JT,et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice[J].Cell Metabolism,2013,17(5):790-797.
[2]潘婕,罗本燕.眩晕的诊断与鉴别诊断[J].中国实用内科杂志.2011,31(6):421-423.
[3]王维治.神经病学[M]. 5版.北京:人民卫生出版社,2005:20-22.
[4]周仲瑛.中医内科学[M].北京:中国中医药出版社,2007:299.
[5]郑筱萸.中药新药临床研究指导原则(试行)[S].北京:中国医药科技出版社,2002:24.
[6]景小莉,崔应麟.萸竹定眩丸治疗痰浊中阻型眩晕40例[J].中国中医药现代远程教育,2010,8(15):12.
[7]Matuszek B,Lenart-Lipinska M,Duma D,et al. Evaluation of concentrations of FGF-21-a new adipocytokine in type 2 diabetes[J]. Endokrynologia Polska,2010,61(1):50-54.
[8]Mraz M,Barlova M,Lacinova Z,et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity[J]. Clin Endocrinol,2009,71(3):369-375.
[9]Omar BA,Andersen B,Hald J,et al. Fibroblast growth factor 21(FGF21)and glucagon like peptide I contribute to diabetes resistance in glucagon receptor deficient mice[J]. Diabetes,2014,63(1):101-110.
[10]Holland W L,Adams A C,Brozinick JT,et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice[J].Cell Metabolism,2013,17(5):790-797.